Tag: Datroway EGFR-mutated NSCLC

Home / Datroway EGFR-mutated NSCLC

Categories

Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer

On June 23, 2025, the Food and Drug Administration conferred accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or metastatic epiderm...
datroway-egfr-mutated-nsclc

Scan the code